John Helmer continues with his discussion of the considerable gaps in information regarding the MH17 crash, and how some of the evidence is missing by virtue being withheld from the public, as opposed to not available
Read more...Dan Primack of Fortune has weighed in on what he calls the private equity “mess” at CalPERS, in an important new story, “CalPERS still can’t get out of its own way on private equity.”
Read more...A top journal excoriated two doctors who engaged in disrespectful behavior, but is vastly less vigilant or heated when faced with health care corruption, as in the sort of conduct that can and often does kill people.
Read more...Yves here. Richard Smith is on the trail of what looks to be his biggest international scam find ever, orders of magnitude larger than the usual below the radar single to low double digit million dollar/pound/euro operation that he has ferreted out in the past. And mind you, even though he focuses on the dubious […]
Read more...Richard Smith’s relentless gumshoe work has put a rancid fraud-enabler, GXG Global Exchange Group, out of business.
Read more...Campaigners for the Orwellianly-named “Safe and Accurate Food Labeling Act of 2015” falsely demonize those who want GM labeling as anti-science.
Read more...Power 8, Sponsor of Everton FC, Fulham FC and RCD Espanyol, is a $250Mn Pyramid Fraud.
Read more...Bloomberg runs our op ed on how private equity investors have been so feckless that they deserve to lose their accredited investor status.
Read more...How shocking images of the Vietnam war helped stoke the antiwar movement of the 1960s, and how we’ve since become inured to them and the horrors of war generally.
Read more...A successful initiative in the UK to obtain more registration and publication of clinical trial data has had its US launch utterly ignored , not simply the mainstream media but also the logical suspects in the medical trade press and scholarly journals..
Read more...Another example of the corruption of science: the press falls all over itself hyping Praluent, a new cholesterol-lowering drug with remarkably inconclusive clinical trial data behind it. As Roy Poses points out, “The clinical benefit of the drug was not evident in this trial.”
Read more...By Nathan Tankus, a writer from New York City. Follow him on Twitter at @NathanTankus International political economy is filled with an alphabet soup of organizations that govern all different areas of economic life. Journalists and other commentators tend to talk about these organizations like they have singular positions and immutable opinions. They do not. Instead […]
Read more...Nathan Tankus reports on the latest developments in the IMF staff’s growing war against a deal. Can they succeed in sowing dissent?
Read more...The scandal over CalPERS’ failure to track “carry fees” has the industry worried enough that it is offering up ludicrous rationalizations.
Read more...Filling in some details on a bombshell report about a call that Varoufakis had with hedge fund managers about a parallel currency.
Read more...